Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study
BioDrugs · 2026
DOI: 10.1007/s40259-026-00801-0 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift BioDrugs, 2026. Verfasst von Xin Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Clinical Research Plan of SHDC, Clinical Research Program of Shanghai Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Continuous biologic therapy achieves psoriasis control but may be limited by cost, adherence burden, safety concerns, and patient preference. Evidence on outcomes after early, patient-driven discontinuation of secukinumab in routine practice is limited.
Objective
The aim of this study was to describe clinical outcomes after voluntary secukinumab discontinuation among patients achieving predefined week-12 response targets and to explore factors associated with relapse.
Methods
This prospective single-center cohort enrolled 172 adults with moderate-to-severe plaque psoriasis initiating secukinumab during 2022–2024. At week 12, patients achieving target response achievement 1 (TRA1: Psoriasis Area and Severity Index [PASI]75, Physician’s Global Assessment [PGA] 0/1, or body surface area [BSA]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Traditional Chinese Medicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Institute of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Dermatology Center, Jinhua Fifth Hospital, Zhejiang, China.
- School of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Förderung
- Clinical Research Plan of SHDC
- Clinical Research Program of Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Intelligence Fund of Shanghai Skin Disease Hospital
- Shanghai Key Discipline Construction Project of Traditional Chinese Medicine
- Youth Talent Promotion Project of China Association of Traditional Chinese Medicine (2024-2026) Category B
- Shanghai Oriental Talents Program Youth Project (Health Platform)
Zitieren
APA
Ma, X., Jiang, Y., Liu, D., Xu, Q., Shen, F., Duan, Z., Gao, X., Zhang, X., Cai, R., Zhang, R., Li, B., & Wang, R. (2026). Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study. BioDrugs. https://doi.org/10.1007/s40259-026-00801-0
Vancouver
Ma X, Jiang Y, Liu D, Xu Q, Shen F, Duan Z, et al. Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study. BioDrugs. 2026. doi:10.1007/s40259-026-00801-0
BibTeX
@article{Ma2026,
author = {Ma, Xin and Jiang, Yue and Liu, Dongmei and Xu, Quanruo and Shen, Fanlingzi and Duan, Zhen and Gao, Xiangjin and Zhang, Xiuqi and Cai, Ruiqi and Zhang, Rui and Li, Bin and Wang, Ruiping},
title = {Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study},
journal = {BioDrugs},
year = {2026},
doi = {10.1007/s40259-026-00801-0}
}
EUVIMED